Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2016; 22(30): 6906-6916
Published online Aug 14, 2016. doi: 10.3748/wjg.v22.i30.6906
Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies
Yan Li, Yun-Feng Zhou, Han Liang, Hua-Qing Wang, Ji-Hui Hao, Zheng-Gang Zhu, De-Seng Wan, Lun-Xiu Qin, Shu-Zhong Cui, Jia-Fu Ji, Hui-Mian Xu, Shao-Zhong Wei, Hong-Bin Xu, Tao Suo, Shu-Jun Yang, Cong-Hua Xie, Xiao-Jun Yang, Guo-Liang Yang
Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China
Yan Li, Yun-Feng Zhou, Cong-Hua Xie, Xiao-Jun Yang, Guo-Liang Yang, Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Wuhan 430071, Hubei Province, China
Han Liang, Hua-Qing Wang, Ji-Hui Hao, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Study Center, Tianjin 300060, China
Zheng-Gang Zhu, Ruijin Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200025, China
De-Seng Wan, Cancer Hospital Affiliated to Sun Yat-Sen University, Guangzhou 510060, Guangdong Province, China
Lun-Xiu Qin, Department of General Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
Shu-Zhong Cui, Cancer Hospital Affiliated to Guangzhou Medical University, Guangzhou 510095, Guangdong Province, China
Jia-Fu Ji, Cancer Hospital Affiliated to Peking University, Beijing 100142, China
Hui-Mian Xu, Department of Surgical Oncology, the First Hospital Affiliated to China Medical University, Shenyang 110001, Liaoning Province, China
Shao-Zhong Wei, Hubei Cancer Hospital, Wuhan 430079, Hubei Province, China
Hong-Bin Xu, Beijing Aeronautics Central Hospital, Beijing 100008, China
Tao Suo, Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
Shu-Jun Yang, Cancer Hospital of Henan Province Affiliated to Zhengzhou University, Zhengzhou 450008, Henan Province, China
Author contributions: Yan Li wrote and revised the paper; all authors have read and approved the final manuscript.
Supported by Key Project of the National Natural Science Foundation of China, No. 81230031.
Conflict-of-interest statement: The authors declare that there is no potential conflict of interest related to this study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yan Li, MD, PhD, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, No 10, Tieyi Road, Yangfangdian, Haidian District, Beijing 100038, China. liyansd2@163.com
Telephone: +86-10-63926522 Fax: +86-10-63926522
Received: February 1, 2016
Peer-review started: February 2, 2016
First decision: March 7, 2016
Revised: April 2, 2016
Accepted: June 13, 2016
Article in press: June 13, 2016
Published online: August 14, 2016
Processing time: 184 Days and 22.4 Hours
Abstract

Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis (PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases I, II and III clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China.

Keywords: Expert consensus; Peritoneal carcinomatosis; Cytoreductive surgery; Intraperitoneal hyperthermic chemotherapy; Gastric cancer; Colorectal cancer; Ovarian cancer; Peritoneal mesothelioma; Pseudomyxoma Peritonei; Peritoneal sarcoma

Core tip: Cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered as the standard treatment for selected patients with peritoneal carcinomatosis (PC) in many established cancer centers worldwide. This Chinese expert consensus summarizes the mechanism of CRS + HIPEC to treat PC and its clinical efficacy in gastric cancer, colorectal cancer, ovarian cancer, pseudomyxoma peritonei, malignant peritoneal mesothelioma, and peritoneal sarcoma. Furthermore, a clinical pathway of CRS + HIPEC to treat PC has also been formulated.